Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Myriad Genetics Sells EndoPredict Unit to Eurobio, Refocuses Strategy
Tech & Innovation Myriad Genetics Sells EndoPredict Unit to Eurobio, Refocuses Strategy

In a recent strategic maneuver, Myriad Genetics, Inc., known for its pioneering work in genetic testing and precision medicine, officially announced the sale of its EndoPredict business unit to Eurobio Scientific. Based in Salt Lake City, Utah, Myriad's decision aligns with broader plans to

Can ZMA001 Revolutionize PAH Treatment With FDA Orphan Drug Designation?
Research & Development Can ZMA001 Revolutionize PAH Treatment With FDA Orphan Drug Designation?

Pulmonary arterial hypertension (PAH) is a debilitating and life-threatening condition characterized by the blockage and narrowing of pulmonary arterioles. Current treatment options primarily focus on symptomatic relief, especially through the use of vasodilators. These medications help widen blood

Global Automation in Biopharma Market to Surge by 2031: Key Trends and Forecasts
Management & Regulatory Global Automation in Biopharma Market to Surge by 2031: Key Trends and Forecasts

Global Automation in Biopharma Market to Surge by 2031: Key Trends and Forecasts The global biopharma market is on the cusp of remarkable transformations driven by automation, enabling more efficient production processes and improved product quality. This evolving sector is undergoing significant

Cartesian’s Descartes-08 Shows Promise in Myasthenia Gravis; Market Wary
Research & Development Cartesian’s Descartes-08 Shows Promise in Myasthenia Gravis; Market Wary

The field of autoimmune disease treatment is witnessing groundbreaking innovations, with Cartesian Therapeutics making headlines for its latest Phase 2 clinical trial results of Descartes-08. This experimental cell therapy aims to bring hope to patients suffering from myasthenia gravis, a rare and

Capra Biosciences Secures $7.5M for AI-Driven Biomanufacturing Project
Management & Regulatory Capra Biosciences Secures $7.5M for AI-Driven Biomanufacturing Project

The biomanufacturing industry is on the cusp of a transformative era, driven by technological innovations and strategic financial investments. A recent $7.5 million project agreement awarded to Capra Biosciences by the U.S. Department of Health and Human Services’ Administration for Strategic P

Enhancing Data Integrity in Pharma with Automation to Meet ALCOA+
Management & Regulatory Enhancing Data Integrity in Pharma with Automation to Meet ALCOA+

Pharmaceutical manufacturing is evolving rapidly to keep pace with increasing global demand and stringent regulatory standards. A critical aspect of this evolution is the integration of automation systems to enhance data integrity. Automation ensures compliance with the ALCOA+

SK Biopharma Secures $571.5M Deal with Full-Life for Cancer Drug FL-091
Research & Development SK Biopharma Secures $571.5M Deal with Full-Life for Cancer Drug FL-091

The recent $571.5 million licensing agreement between SK Biopharmaceuticals Co., Ltd., and Full-Life Technologies Limited marks a significant milestone in the biotech industry. This exclusive deal grants SK Biopharmaceuticals the rights to develop, manufacture, and commercialize FL-091, an

Can Roche's New Obesity Pill CT-996 Revolutionize Weight Loss?
Research & Development Can Roche's New Obesity Pill CT-996 Revolutionize Weight Loss?

The global obesity epidemic has led to an urgent demand for innovative and effective treatments. Traditional methods like diet, exercise, and surgical interventions present various challenges, often marked by inconsistent results and reduced patient compliance. In response, the pharmaceutical

Merck Launches GMP Manufacturing Line in China for Custom Cell Culture Media
Biotech & Bioprocessing Merck Launches GMP Manufacturing Line in China for Custom Cell Culture Media

Merck has unveiled its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This state-of-the-art facility is located at the Life Science Center in Nantong. The endeavor is backed by a substantial €6.6 million ($7.1 million) investment and aims to meet the burgeoning d

How Will Cardurion's $260M Funding Transform Heart Disease Treatment?
Research & Development How Will Cardurion's $260M Funding Transform Heart Disease Treatment?

Cardurion Pharmaceuticals has recently made headlines by securing a $260 million Series B financing round. This substantial investment underscores the fierce commitment to advancing the treatment of heart disease, one of the leading causes of mortality worldwide. The funds raised will propel

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later